Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · APGE · as of Mar 31, 2025
Ownership Breakdown
179
Institutional Holders
▲ 16 vs Q4
$2.32B
Total Inst. Value
▼ $304.99M vs Q4
61.90M
Shares Outstanding
freeFloat 92.01%
72.19M
13F Shares Held
▲ 14.31M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
APGE largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
OCTAGON CAPITAL ADVISORS LP biological products, (no diagnostic substances) | 10.70M | 18.39% | 18.39% | $14.87B | May 15, 2025 | NEW |
VR ADVISER, LLC biological products, (no diagnostic substances) | 8.49M | 14.59% | 14.59% | $317.31B | May 15, 2025 | — held |
FMR LLC biological products, (no diagnostic substances) | 7.49M | 12.88% | 12.88% | $279.96B | May 12, 2025 | ▼ 5.8K |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 5.49M | 9.43% | 9.43% | $204.95B | May 13, 2025 | ▲ 968.4K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.91M | 5.00% | 5.00% | $108.75B | May 2, 2025 | ▼ 134.1K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 2.71M | 4.66% | 4.66% | $101.32B | May 15, 2025 | — held |
DRIEHAUS CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.34M | 4.02% | 4.02% | $87.41B | May 15, 2025 | ▼ 265.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.08M | 3.58% | 3.58% | $77.81B | May 9, 2025 | ▼ 15.0K |
FAIRMOUNT FUNDS MANAGEMENT LLC biological products, (no diagnostic substances) | 2.05M | 3.52% | 3.52% | $76.54B | May 15, 2025 | — held |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 1.79M | 3.08% | 3.08% | $71.29B | May 15, 2025 | ▲ 658.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
22
Increased
+5.93M shares4
New Positions
first time holders18
Decreased
−2.04M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.89M
+5.93M / −2.04M
Net new holders
+8
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
APGE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
21
Sell transactions
0.19
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Dambkowski Carl Chief Medical Officer | Jun 3, 2026 | Sale | 5,500 | $78.71 | $432.9K | 205.6K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | May 13, 2026 | Sale | 18,659 | $82.05 | $1.53M | 1.12M | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | May 13, 2026 | Sale | 1,341 | $82.58 | $110.7K | 1.12M | Form 4 ↗ |
Dambkowski Carl Chief Medical Officer | May 6, 2026 | Sale | 3,700 | $83.92 | $310.5K | 208.8K | Form 4 ↗ |
Dambkowski Carl Chief Medical Officer | May 6, 2026 | Sale | 1,800 | $84.60 | $152.3K | 207.0K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 811 | $81.02 | $65.7K | 174.6K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 900 | $82.60 | $74.3K | 173.7K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 289 | $83.16 | $24.0K | 173.4K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | Apr 16, 2026 | Sale | 2,000 | $90.00 | $180.0K | 175.4K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | Apr 8, 2026 | Sale | 17,800 | $82.48 | $1.47M | 1.14M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Apogee Therapeutics, Inc. (APGE) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 7.99%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Apogee Therapeutics, Inc. is OCTAGON CAPITAL ADVISORS LP, holding approximately 10.70 million shares — equal to 18.39% of outstanding shares — as of March 31, 2025.
A total of 179 institutional investors currently hold APGE stock, with a combined institutional value of approximately $2.32 billion as of the most recent 13F filing period.
Frequently asked questions
APGE ownershipApogee Therapeutics, Inc. (APGE) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is OCTAGON CAPITAL ADVISORS LP with a 18.39% stake. Company insiders hold 7.99%. Data sourced from SEC Form 13F as of March 31, 2025.